SCHEMBL7602780

SCHEMBL7602780

Cc1ccc(-c2nc3ccc(C)cn3c2C(=O)C(=O)Cl)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
GABRA1 P14867 3/20 0.53
GABRB2 P47870 3/20 0.53
KDM4E B2RXH2 2/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
LMNA P02545 1/20 0.53
ALB P02768 1/20 0.53
CYP3A4 P08684 1/20 0.53
CHRM1 P11229 1/20 0.53
GABRB1 P18505 1/20 0.53
GABRG2 P18507 1/20 0.53
GABRB3 P28472 1/20 0.53
GABRA3 P34903 1/20 0.53
ADRA1A P35348 1/20 0.53
OPRK1 P41145 1/20 0.53
HTR2B P41595 1/20 0.53
GABRA2 P47869 1/20 0.53
KCNH2 Q12809 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7602118 0.87 NPC1 (0.60) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL6012095 0.84 RAB9A (0.59) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL4259535 0.83 RAB9A (0.57) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL7011129 0.82 ALDH1A1 (0.74) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL13069156 0.81 NPC1 (0.53) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL7820531 0.77 NPC1 (0.72) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL2929147 0.77 GABRB2 (0.73) GABRA1GABRB2KDM4EHPGDHSD17B10
Hydrochloric Acid SCHEMBL2935064 0.76 GABRB2 (0.71) GABRA1GABRB2KDM4EHPGDHSD17B10
SCHEMBL1761262 0.75 RAB9A (0.49) NPC1RAB9AGABRA1GABRB2KDM4E
SCHEMBL8288559 0.74 TP53 (0.59) NPC1RAB9AGABRA1GABRB2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183377-B2 Process for the preparation of imidazopyridines ELDER PHARMACEUTICALS LTD. 2012-05-22 US disclosed
US-8183377-B2 Process for the preparation of imidazopyridines ELDER PHARMACEUTICALS LTD. 2012-05-22 US disclosed
EP-1917263-B1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES ELDER PHARMACEUTICALS LTD (IN) 2010-11-24 EP disclosed
US-20100036129-A1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES ELDER PHARMACEUTICALS LTD. (IN) 2010-02-11 US disclosed
US-20100036129-A1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES ELDER PHARMACEUTICALS LTD. (IN) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036129-A1 PROCESS FOR THE PREPARATION OF IMIDAZOPYRIDINES OTC, ODC1, OGDH NPC1 3053/4885RAB9A 2279/4885GABRA1 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.